Insights On Upstream Manufacturing
-
Bioreactor Modeling To De-risk Scale-Up And Scale-Down Across The Product Lifecycle
11/2/2026
Learn how bioreactor modeling can reduce scale-up and transfer risk by creating more representative downscale models for process characterization, troubleshooting and manufacturing transfers, including an example comparing traditional scale-down methods with a shear stress-based approach.
-
Scale-Up And Tech Transfer Of A Cell Culture Process From 1000 L To 2 X 2000 L
11/2/2026
See how a cell culture process scaled across two manufacturing sites while maintaining comparable performance and product quality amid changing requirements
-
Scale-up Challenges In Bioreactors: Why Not Every Parameter Can Stay Constant
11/2/2026
Explore how power input, tip speed, mixing, oxygen transfer, sparger geometry and shear forces change with scale, and why equipment knowledge and process experience are critical to informed scale-up decisions.
-
The Importance Of Starting Material In Breakthrough Cancer Treatments
11/2/2026
Autologous TIL therapy starts with patient biology no developer can standardize. Discover which parts of the process can be controlled, and how far that goes toward reproducible products.
-
Breaking The DoE Bottleneck In Biologics Development
10/29/2026
Advanced screening designs reduce experimental burden while identifying critical process parameters, accelerating biomanufacturing optimization and process development.
-
Biologics Characterization Through Machine Learning
10/29/2026
Space-filling designs and ensemble machine learning can characterize a six-factor gene therapy process in just 24 runs, reducing time and materials.
-
Collaborating For Supply Chain Resilience
10/28/2026
Cell culture media supply resilience shapes continuity. A global CDMO's approach to tariff exposure spans both proprietary formulations and standard media, showing how supply strategy holds up.
-
Enabling Commercial-Scale Biologics Manufacturing With Media Services
10/28/2026
Consistent cell culture media across development underpins reliability at scale. Integrated manufacturing addresses supply, quality, and shelf-life uncertainty that can ripple into commitments.
-
Rethinking Starting Material: Whole Blood For Autologous T-Cell Manufacture
10/28/2026
Matching starting material to process requirements in autologous T-cell manufacturing, and where whole blood may stand in for leukapheresis without compromising what the process needs.
-
3-In-1 Protocol For Rapid CAR-T Cell Manufacturing
10/28/2026
Closing the process and merging three steps into one perfusion run brings CAR-T manufacturing down to roughly a week, with fewer open events and lower batch failure risk.